Today's Rundown Featured Story | | | Tuesday, November 12, 2019 Amgen has given notice of its intent to lay off 149 people at its Cambridge, Massachusetts, operation by the end of the year. The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations in a move that would threaten around 180 jobs. |
|
|---|
|
Top Stories Tuesday, November 12, 2019 A new clinical hold following serious adverse events are the latest in a string of setbacks for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy. Tuesday, November 12, 2019 AstraZeneca is planning to file for approval of anifrolumab in systemic lupus erythematosus in the second half of next year. The Big Pharma is confident data generated across mid- and late-phase trials show the anti-IFNAR1 antibody works despite a pivotal study missing its primary goal. Tuesday, November 12, 2019 BOSTON—Durect presented data showing that all 19 patients who received its alcoholic hepatitis (AH) treatment were still alive 28 days after treatment. The drug also lowered bilirubin, a marker of liver disease, and reduced scores that reflect the likelihood that a person with AH will die within a certain period of time. Tuesday, November 12, 2019 BOSTON—VBI's Sci-B-Vac protected fewer people after the second dose than GlaxoSmith Kline's Engerix-B did after the third dose, but it protected twice as many people at every time point in the study up until the third dose. In a world where people aren’t very good at completing their vaccinations, it’s important to have a vaccine that acts quickly. Monday, November 11, 2019 Just one month after ending a nine-year partnership with AbbVie, Reata Pharmaceuticals is delivering phase 3 data for its lead program in a rare form of chronic kidney disease. Patients who received the drug had better kidney function after 48 weeks of treatment and sustained that improvement after stopping the drug for four weeks. Monday, November 11, 2019 Regenxbio is taking the FDA to court over a clinical hold. The lawsuit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation of the regulatory action. Tuesday, November 12, 2019 NASH frontrunner Intercept Pharma presented a secondary analysis of its Regenerate study that found that treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests. Enrollment Showcase Resources Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 
